News
EverQuote posts record Q2 2025 profitability, highlighting 34% revenue growth, AI-driven efficiency, and a $50M share buyback.
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback